Larimar Therapeutics, Inc.

What they do

Larimar uses a cell penetrating peptide (CPP) platform to deliver therapeutic molecules to intracellular targets. Its lead candidate, nomlabofusp, is a recombinant fusion protein intended to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA). The company has completed four clinical studies and has an ongoing open label study in adults and adolescents, supported by third-party manufacturing.

Revenue drivers

• Product revenue — None. XBRL shows $0.00 annual revenue from 2015 through 2019, and nomlabofusp remains investigational with no approved product.
• Government grants or collaboration revenue — No grant or collaboration revenue is disclosed in the provided filings or financial data.
• Future nomlabofusp sales — The only stated commercial path is potential approval and sale of nomlabofusp for Friedreich's ataxia; no approval or launch has occurred.
• Platform out-licensing — Management states the CPP platform may target additional orphan indications, but no licensing agreements or related revenue are disclosed.

Recent performance

The company reported a net loss of $165.7 million for 2025 versus $80.6 million for 2024, with operating cash use of $113.2 million in 2025. As of June 30, 2026, total assets were $165.3 million, total liabilities $37.9 million, and shareholder equity $127.4 million, including $92.7 million in cash and equivalents. The August 2026 earnings release cites $156.3 million in cash, cash equivalents and marketable securities as of June 30, 2026. In June 2026, Larimar reported that 43 participants had received at least one dose in the OL study, more than 10,000 doses had been administered, and 22 participants remained in the study.

Strategy

Larimar is pursuing a rolling Biologics License Application for nomlabofusp seeking accelerated approval, with the first module submitted and completion expected in the second half of 2026. It plans to dose the first patient in a global confirmatory Phase 3 study in the third quarter of 2026. The company holds FDA Breakthrough Therapy, Orphan Drug, Fast Track, and Pediatric Rare Disease designations, plus EMA PRIME and UK ILAP access, and is participating in the FDA's START pilot program. It is also building sales, marketing and distribution capabilities ahead of a potential launch.

Risks

• No product revenue and recurring losses — Larimar has generated no annual revenue in the reported periods and had a 2025 net loss of $165.7 million and an accumulated deficit of $434.8 million as of December 31, 2025.
• Anaphylaxis and safety events in the OL study — Ten participants experienced anaphylaxis and discontinued the OL study, including nine with prior nomlabofusp exposure, and anaphylaxis has been identified as a likely adverse drug reaction.
• Regulatory and clinical uncertainty — Nomlabofusp is investigational, the rolling BLA and planned Phase 3 study have not been completed, and no assurance exists that accelerated approval or any approval will be granted.
• Cash runway dependence on financing — The company's projected runway is into the third quarter of 2027 and previously into the second quarter of 2027, requiring additional capital to fund ongoing development and potential commercialization.

Outlook

Management expects to complete the rolling BLA submission for nomlabofusp in the second half of 2026 and to begin dosing the first patient in the global confirmatory Phase 3 study in the third quarter of 2026. Larimar reports projected cash runway into the third quarter of 2027 and continues enrolling the open label study, with additional participants dosed in July and several adults and adolescents in screening. No revenue guidance is provided because the company has no approved products.